Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone

Stock Track

Mar 31

IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.

The biopharmaceutical company announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306 is described as the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development.

The drug candidate works by blocking the "don't eat me" signal through inhibition of CD47-SIRPα interaction while enhancing interactions to activate immune cells. It preferentially binds to CD20 over CD47, aiming to effectively eliminate malignant B cells with minimized toxicity. The company holds global intellectual property and commercialization rights for IMM0306.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1139291031"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139291031\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139291031?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139291031","market":"nz","top_or_hot":-1,"title":"Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone","media":"Stock Track","content":"<p>IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.</p><p>The biopharmaceutical company announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306 is described as the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development.</p><p>The drug candidate works by blocking the \"don't eat me\" signal through inhibition of CD47-SIRPα interaction while enhancing interactions to activate immune cells. It preferentially binds to CD20 over CD47, aiming to effectively eliminate malignant B cells with minimized toxicity. The company holds global intellectual property and commercialization rights for IMM0306.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-31 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.</p><p>The biopharmaceutical company announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306 is described as the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development.</p><p>The drug candidate works by blocking the \"don't eat me\" signal through inhibition of CD47-SIRPα interaction while enhancing interactions to activate immune cells. It preferentially binds to CD20 over CD47, aiming to effectively eliminate malignant B cells with minimized toxicity. The company holds global intellectual property and commercialization rights for IMM0306.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1139291031","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139291031","pubTimestamp":1774922528,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.The biopharmaceutical company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"个股追踪|IMMUNEONCO-B盘中大涨5.15%三期临床试验里程碑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.The biopharmaceutical company announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306 is described as the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development.The drug candidate works by blocking the \"don't eat me\" signal through inhibition of CD47-SIRPα interaction while enhancing interactions to activate immune cells. It preferentially binds to CD20 over CD47, aiming to effectively eliminate malignant B cells with minimized toxicity. The company holds global intellectual property and commercialization rights for IMM0306.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}